BEXIMCO PHARMACEUTICALS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 116.1 BDT | -0.43% |
|
-1.36% | -20.59% |
| Mar. 04 | Beximco names Iqbal Ahmed as managing director | AN |
| Jan. 30 | Beximco Pharmaceuticals to strengthen portfolio as interim profit up | AN |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -20.59% | 474M | - | ||
| +24.17% | 562B | B | ||
| -6.33% | 358B | C+ | ||
| +19.90% | 322B | B- | ||
| +7.95% | 297B | C+ | ||
| +13.45% | 219B | B+ | ||
| +6.04% | 199B | B- | ||
| -10.51% | 196B | A+ | ||
| -12.26% | 149B | C+ | ||
| -6.47% | 146B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
- Stock Market
- Equities
- BXPHARMA Stock
- Ratings Beximco Pharmaceuticals Limited
